NC-PERCONA
17.5.2022 18:06:05 CEST | Business Wire | Press release
Percona , a leader in open source database software and services, today announced the general availability of Percona Platform , which brings the company’s expertise with databases including MySQL®, PostgreSQL® and MongoDB® together alongside services, management and automated insights into a single product. Using the company’s experience in managing and improving some of the largest database installations in the world, Percona Platform helps users monitor, manage, secure and optimize their database instances across any infrastructure.
“Percona Platform brings the experience and expertise that we have built up over the years and puts it in the hands of developers and database administrators to use. It includes AI-powered recommendations that help users improve performance, management and security, as well as making it easier to scale up and manage their instances over time. With Percona Platform, we thought about how to improve the experience for developers and DBAs around running their data workloads, and how to help people achieve their goals faster around managing databases as part of their overall approach,” said Donnie Berkholz, Senior Vice President Product at Percona.
“Developers want to improve their efficiency and experience across their tasks, and databases are no exception. Improving this will be an area of investment for companies - whether this involves time for their staff to implement projects, or investing in cloud services to provide the tools they need. Percona’s approach to this challenge aims to provide self-managed control and internal ownership as well as the flexibility and ease of use that many companies tout with their DBaaS offerings. By offering a fully open source compatible service, Percona is looking to plug a gap in the market that many database companies are not able to cover,” commented Bradley Shimmin, Chief Analyst, AI platforms, analytics and data management at Omdia.
“There has been an explosion of data tools available to enterprises, which in turn has led to rampant fragmentation and highly complex, disjointed workflows. Organizations that prize velocity are looking for ways to integrate various data tools into their broader development workflows and monitor them. This is the opportunity that Percona Platform is built for. The combination of software and services in this space is intended to help customers better manage their database deployments,” commented Rachel Stephens, Senior Analyst, RedMonk.
“Percona has woven over a decade of open-source database expertise into a consistent, modern database experience for all organizations, from any cloud to on-premises. With Percona Platform we have built out our open source database software offerings, bolstered by automated insights, self-service operations, and the best database observability and management tools in the market. This launch will help us scale our business and create a sustainable model in the age of cloud, while respecting the freedom and accessibility that is open source. We have seen other companies turn away from open source and adopt closed source licenses in order to maximize their profitability, which we think is not in the best interests of customers. Our approach makes our expertise available to all our customers and users, putting their needs first,” added Ann Schlemmer, President at Percona.
Percona Platform is the culmination of the company’s work to expand and deliver its wide-ranging knowledge of databases into products that users can deploy quickly and use to improve their performance. As part of the launch, Percona has used its service expertise to create automated recommendation products called Advisors for customers that can help them immediately improve their results. It supports all deployment configurations, from public, private and hybrid cloud instances through to internal data center deployments. It supports both self-managed and Percona-managed instances, letting customers approach their database management in the way that suits them.
Percona Platform includes the following elements:
- Percona Portal - access to all Percona services and product expertise through one unified online portal, covering multiple databases with enterprise-level features including backup, security, management, optimization and more
- Percona Monitoring and Management (PMM) - a database management product that is fully open source itself, allowing developers and DBAs to streamline their management tasks across multiple platforms from one place
- New range of Advisors - automated insights that ensure user databases are performing at their best, including security management, configuration and performance improvements
- Private DBaaS Technical Preview - this will support companies deploying their own DBaaS internally using open source database distributions, Percona management tool PMM and Kubernetes operators for MySQL and PostgreSQL. It will also support the same approach for MongoDB. This enables users to easily provision and manage database instances on a self-service basis across development and testing instances, improving the experience for developers
- Percona Account - simplified user account management for all Percona products and services under one account
Links
- Percona Platform - https://www.percona.com/software/percona-platform
About Percona
Databases run better with Percona. Percona is the only company that delivers enterprise-class products, support and services for a range of open source databases including MySQL®, MariaDB®, MongoDB®, and PostgreSQL across traditional deployments, cloud-based platforms and hybrid IT environments. The company is committed to supporting open source as an approach to software licensing, development and deployment - its database management tools are used by millions of application developers, database administrators and IT professionals worldwide.
Percona equips businesses with the freedom to choose, the freedom to create, and the freedom to make a difference — helping them scale with speed as they grow. The company supports global brands such as PayPal, Vimeo, RockStar Games, Duolingo, Fiserv, Slack, Cisco Systems, and Rent the Runway, as well as smaller enterprises looking to maximize application performance while streamlining database efficiencies. For more information, visit www.percona.com .
Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220517006011/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
